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Abstract
Migraine characterized by recurrent headache episodes presents with aura or 
without. Various treatment modalities ranging from 5-HT1B/1D agonists, non-
steroidal anti-inflammatory drugs (NSAIDs), to steroids are available for acute 
treatment of migraine. Prophylaxis for chronic cases usually encompasses β block-
ers, calcium channel blockers, and antiepileptics. Many nutraceutical preparations 
are helpful in migraine, including riboflavin and vitamin B12. This review focuses on 
the newer agents available for treatment of migraine with some insights into their 
clinical trials.
Keywords: headache, nutraceutical, prophylaxis, triptans, cortical spreading 
depression
1. Introduction
The word “migraine” comes from the Greek ἡμικρανία (hemikrania), “pain on one 
side of the head”; ἡμι- (hemi-), “half”; and κρανίον (kranion), “skull.” The disorder 
may also be described as a vascular headache associated with changes in the size of 
the arteries within and outside the brain [1]. It is usually accompanied by a plethora 
of comorbidities influencing its clinical expression and complicating its treatment, 
making migraine a chronic and debilitating neurological disorder. It is a polygenetic 
disease with high susceptibility to epigenetic factors affecting millions of people 
worldwide. This is mainly because of changes in hormonal levels. It is estimated 
that up to 15% of people suffer from migraine worldwide with 1.4–2.2% affected by 
the chronic form of the disease [2, 3]. Global data shows the prevalence of migraine 
increasing during adolescence with peaks in midlife and the prevalence declining 
rapidly after 50 years. Migraine presents as headache and visual, auditory, olfactory, 
and cutaneous stimuli hypersensitivity along with nausea and vomiting [4]. Both 
environmental and genetic factors play a role in the development of migraine with 
more than two third of cases having familial history [5]. Boys are more affected than 
girls before puberty, but women are more affected than men as age increases [6].
2. Signs and symptoms
Migraine is self-limiting, usually presenting as recurrent severe headache. It is 
associated with autonomic symptoms. It presents with aura in 15–30% and without 
aura in the rest [7]. Migraine varies from person to person with respect to severity 
of pain, duration of attack, and its frequency. A migraine lasting longer than 72 h is 
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1. Specific treatment
a. Triptans
b. Ergot and its derivatives
2. Nonspecific treatment
a. Antiemetics
b. NSAIDs and nonnarcotic analgesics
c. Narcotics/opiate analgesics
Table 1. 
Treatment of acute migraine attacks.
termed status migrainosus. Different phases of migraine include the prodrome, the 
aura, the pain, and the postdrome. The prodromal phase occurs hours before the 
headache in 60% of patients, the aura usually precedes headache in 15–20%, severe 
headache occurs in the pain phase, and the postdromal phase usually follows the 
attack of migraine [8].
3. The pathophysiology of migraine
The best solutions to medical conditions come only from understanding the 
pathophysiology of the disease state. As per Wolff ’s vascular theory, vascular 
constriction leading to hypoperfusion of the cortex later followed by vascular 
dilation was put forward as the main pathophysiological mechanism. Currently 
neurovascular hypothesis involving the trigeminovascular system is considered. 
Another hypothesis includes mutations of neuronal calcium channels, leading to 
hypersensitivity, resulting in migraine attacks. It is also postulated that increased 
dopaminergic activity in the thalamus/hypothalamus causing modulation in central 
pain pathways also plays a role in migraine attacks. Other mechanisms put forward 
include cortical spreading depression; release of vasoactive peptides like substance 
P, calcitonin gene-related peptide (CGRP) from trigeminal neural endings, nitric 
oxide, and serotonin; excess activation of N-methyl-d-aspartate receptor (NMDA) 
receptors without modulation by brain stem pain centers due to dysfunction of 
these centers; overactivity of excitatory neurotransmitters like aspartate and gluta-
mate causing neuronal excitability; and finally neurogenic inflammation which play 
an important role in migraine attack development [9–12].
4. Treatment of migraine
It can be divided into treatment of acute attacks and treatment of chronic 
migraine. As per the US consortium (2000), recommended guidelines [13] for 
treatment of acute migraine include pharmacological and non-pharmacological 
modalities as shown in Table 1.
5. Specific treatment
5.1 Triptans
Triptans are selective agonists of 5-HT1B and 5-HT1D receptors. The mechanism 
of action includes intracranial vessel vasoconstriction (5-HT1B), peripheral neuronal 
inhibition (5-HT1D), and presynaptic dorsal horn stimulation (5-HT1D), produc-
ing second-order brain stem neuronal inhibition. Triptans influence the function 
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of 5-hydroxytryptamine 1F (5-HT1F) receptors and enhance descending inhibitory 
pain pathways. Triptans reduce—to a considerable extent—pain severity in 2 h as 
per randomized controlled trials. Oral formulations are usually preferred over other 
formulations, but 6 mg subcutaneous injection of sumatriptan appears to be the most 
efficacious. As per current evidence, all oral formulations have equal efficacy except 
for frovatriptan which is less efficacious but has longer duration action. Parenteral 
preparations are more useful than oral ones, but the choice of medications depends 
on the clinician as well as the patient. Triptans are the first-line drugs used in acute 
treatment of moderate-to-severe migraine with the best pain relief occurring if it is 
taken within 30 min of attack, and a second dose is usually recommended after 2–4 h 
of initial dose. It is best used in combination with antiemetics and NSAIDs. Adverse 
effects include serotonin syndrome when used in combination with selective serotonin 
reuptake inhibitors (SSRIs), and it should be used with caution in patients having 
ischemic heart disease [14–22]. Characteristics of triptans are summarized in Table 2.
6. Ergot and derivatives
Ergots act on multiple receptors including the 5-HT ones, and these account for 
a robust side effect profile. It is used in acute management of migraine. Side effect 
includes nausea as well as severe vasoconstriction. It is contraindicated in patients 
with vascular disease, hepatic problems, renal dysfunction, and hypertension. It is 
avoided in pregnancy. Dihydroergotamine (DHE) is the only preparation available 
and is used both parentally and intranasally. Repeated administration of DHE is 
very effective in refractory cases as well as status migrainosus. It is relatively safe 
and effective but it requires hospital administration [23–25].
7. Nonspecific treatment
7.1 Nonsteroidal anti-inflammatory drugs
Good quality evidence supports the use of NSAIDs alone or in combination with 
specific agents. These drugs in combination with antiemetics are comparable to 
Drugs Half life Maximum daily dose
Group 1: fast-acting triptans
Sumatriptan 3 h 200 mg oral
40 mg intranasal
12 mg subcutaneous
Rizatriptan 2–3 h 30 mg (15 mg if on propranolol)
Almotriptan 3–4 h 25 mg
Zolmitriptan 3 h Two tablets or 10 mg maximum oral daily dose. 
Two sprays or 10 mg intranasal
Eletriptan 4 h 80 mg
Group 2: slow-acting triptans
Frovatriptan 26 h 7.5 mg
Naratriptan 6 h 5 mg
Table 2. 
Triptan characteristics.
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Drugs Formulation Dose used (the dose wording 
should be mg’)
Aspirin Tablet/oral solution 650–1000 mg
Ketorolac Tablet 10 mg
Ketoprofen Capsule 50–75 mg
Ketoprofen-extended release Capsule 200 mg
Diclofenac potassium Tablet/powder 50 mg
Meclofenamate Capsule 50 mg, 100 mg
Ibuprofen Capsule, tablet, oral suspension 400–1, 0 g
Etodolac Tablet/capsule 200–500 mg
Naproxen Tablet 120–550 mg
Naproxen-controlled release Tablet 750–850 mg maximum
Table 3. 
NSAID characteristics.
lower doses of oral triptans. Recently, powdered preparation of diclofenac sodium 
is approved for treatment of acute attack. Ketorolac, administrated IV, can be used 
for emergency management of migraine. NSAIDs need to be used with caution in 
patients with renal toxicity [26–29]. Characteristics of different drugs in this group 
are summarized in Table 3.
7.2 Neuroleptics/antiemetics
Dopamine D2 receptor antagonists can be used alone or in combination to treat 
headache as well as nausea. It is mostly used in emergency settings and is available 
in oral, parenteral, and suppository forms, but concerns over extrapyramidal side 
effects, tardive dyskinesia, and lack of familiarity in their effect on migraine attacks 
restrict their use to a great extent [30–33]. Characteristics of antiemetics are sum-
marized in Table 4.
7.3 Corticosteroids
Steroids are suggested for acute treatment as well as for status migrainosus [34]. 
They act by reducing the neurogenic inflammation and vasogenic edema and also 
play an important role in central serotonergic pathways [35]. One study showed that 
addition of dexamethasone 4 mg per oral to triptans plus NSAID reduces recurrence 
and is well tolerated in patients with frequent attacks [36, 37].
Drug Formulation Dose of migraine
Prochlorperazine Tablet, suppository 5–10 mg
25 mg
Metoclopramide Tablet 10 mg
Chlorpromazine Tablet 10–25 mg
Promethazine Tablet 25–50 mg
Ondansetron Tablet, oral disintegrating tablet 4 mg
8 mg
Table 4. 
Antiemetic characteristics.
5Recent Advances in Migraine Therapy
DOI: http://dx.doi.org/10.5772/intechopen.91286
7.4 Opioids
Opioids are the most prescribed drug for acute and rescue therapy in migraine 
in America. Recent studies have discouraged the use of opioids mainly because it 
decreases gray matter, increases CGRP release, releases pro-inflammatory peptides, 
and also causes glutamate receptor activation. It also results in degranulation of 
mast cells and causes vasodilation. There are many side effects, such as overuse 
headache and disease progression [38, 39].
8. Newer agents
8.1 CGRP antagonists
Based on migraine pathology theories, trigeminal ganglion activation causes 
the activation of nociceptive neurons which leads to subsequent release of 
CGRP. Increased CGRP levels cause plasma protein extrusion, vasodilation, and 
mast cell degranulation, ultimately leading to neurogenic inflammation. Drugs 
which antagonize CGRP include olcegepant, telcagepant, and latest approved mono-
clonal antibodies, namely, erenumab, fremanezumab, and galcanezumab [40]. They 
prevent binding of endogenous CGRP on its receptors and suppress the stimulation 
of CGRP on trigeminal ganglion neurons. They inhibit cortical spreading depression 
[40]. They lack vasoconstrictive effect. Olcegepant is as effective as oral triptans 
with less cardiovascular side effects such as blood pressure increase and tachycardia. 
But one major limitation is intravenous dosing. Telcagepant was initially claimed to 
be as potent as rizatriptan, causing pain relief in 2 h and also sustained pain relief at 
24 h and relief of migraine-associated symptoms with overall good tolerability pro-
file, but later the phase II trial was terminated, claiming the drug showed increase in 
liver transaminases [40]. Eptinezumab is a new drug in this class under trial and is 
not yet approved by the Food and Drug Administration (FDA).
8.2 Lasmiditan
It is a 5-HT1F receptor agonist. In experimental model, it blocks neurogenic 
inflammation, decreases c-fos expression, and lacks vasoconstriction. The main 
postulated mechanisms include inhibition of protein leakage, blockage of second-
ary trigeminal neuronal activation, and inhibition of neuropeptide release like 
glutamate. In a double-blind placebo-controlled parallel group study in 512 patients, 
the oral form and dose of 50, 100, 200, and 400 mg in moderate-to-severe migraine 
attacks proved that it is as effective as sumatriptan without causing vasoconstric-
tion, but the significant drawback is its major side effects in the central nervous 
system. Studies also show a great improvement in headache response in 2 h but also 
show high 24-h headache recurrence rate [41].
8.3 Tezampanel
Tezampanel acts as a competitive antagonist of the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor (subtype GluR5) of 
the ionotropic glutamate receptor family. A randomized triple-blind parallel group 
double-dummy, multicenter trial showed 1.2 mg tezampanel had 69% headache 
response rate when compared to 6 mg s.c. sumatriptan which had a response rate of 
86%. It is effective and well tolerated in migraine. It can be used only via intravenous 
route. Dasolampanel is an orally bioavailable analog of tezampanel. Both drugs were 
never marketed [42]. Other newer agents are summarized in Table 5.
Migraine
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Newer targets and drugs Current status
1. Adenosine receptor agonists [67] • GR79236 and GR190178
• GR79236: carotid vasoconstriction than prejunctional inhibi-
tion of CGRP release
2. NXN-188 [68] • A selective nNOS inhibitor + 5-HT1B/5-HT1D receptor agonist 
inhibits CGRP release in preclinical animal models
3. LY2951742 [69] • Monoclonal antibody to CGRP under trial
4. Orexin receptor antagonism [70] 
(filorexant)
Orexin: trigeminal nociceptive and CSD
RCT: failed efficacy
5. TRPV1 antagonism
(SB-705498) [71]
• Trigeminal nociceptors: heat- and capsaicin-gated channel 
TRPV1
• Peripheral and central sensitization of trigeminovascular 
system
6. Melatonin [72] • Abnormal levels: decreased inhibitory neurotransmission
• Decrease inhibition of release of CGRP
7. P2Y purinergic receptors [73] • Involved in pain signaling and future receptor target
Table 5. 
Newer targets and drugs.
8.4 Prophylaxis
It is indicated when a patient meets the following criteria [43]:
• Four or more migraine days per month.
• Recurring migraines significantly interfere with daily activity.
• Contraindication/failure/overuse—acute therapies.
• Overwhelming costs of acute therapies.
• Uncommon migraine conditions—hemiplegic and basilar migraine.
8.5 Beta blockers
Various beta blockers used are summarized in Table 6. The mechanisms by 
which they act include inhibition of central beta receptors and antagonism of 
5-HT1A and 5-HT1B receptors, thereby reducing neuronal excitability. It inhibits 
nitric oxide (NO) production by blocking inducible nitric oxide synthase and 
Drugs Daily doses
Propranolol 40–400 mg
Nadolol 20–160 mg
Metoprolol 100–200 mg
Atenolol 50–200 mg
Timolol 20–60 mg
Table 6. 
Beta blockers and dosage.
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inhibits excitatory activity of glutamate, thereby reducing neuronal activity. They 
also inhibit kainate-induced currents (synergistic with NMDA blockers) and reduce 
neuronal activity and also have additional membrane-stabilizing action [44, 45].
8.6 Carvedilol: novel β blocker in migraine
In an open-label trial of 76 patients, a dose of 3.125–6.25 mg twice a week 
was used, and it was found that 60% of patients had 50% reduction in monthly 
migraine attack frequency and severity, but in 26% of patients, there was lack of 
efficacy with the drug [46].
8.7 Calcium channel blockers
It inhibits calcium entry and prevents intoxication of cells exposed to cerebral 
hypoxia due to cortical spreading depression [47]. Various drugs used are sum-
marized in Table 7. Other possible mechanisms include inhibition of 5-HT release, 
inhibition of neurovascular inflammation, and cortical spreading depression.
9. Antiepileptics
9.1 Divalproex sodium
It is a combination of valproic acid and sodium valproate. It is used at a dose 
of 500–1500 mg/day. Mechanisms include prolongation of sodium channel inac-
tivation, suppression of calcium-mediated T current, and inhibition of gamma-
aminobutyric acid (GABA) transaminase. Adverse effect includes nausea, vomiting, 
gastrointestinal distress, alopecia, and craniofacial abnormalities in fetus [49].
9.2 Topiramate
Topiramate is a recently approved drug for migraine prophylaxis. Starting dose 
of 15–25 mg at bedtime and increase 15–25 mg/week [50]. Mechanisms include 
blocking of the voltage-gated sodium channel and inhibition of activation of AMPA-
kainate receptor of glutamate, and it also enhances postsynaptic GABAA receptor 
current. Adverse effects include somnolence, fatigue, weight loss, nervousness, and 
precipitation of renal calculi.
9.3 Tiagabine
It inhibits GABA transporter (GAT-1) and thereby reduces GABA uptake into 
the neurons and glia. It is still not approved by the FDA. In an open-label trial of 
Drugs Comment
1. Flunarizine • 5–10 mg (bedtime)
• Used in Europe
2. Verapamil • 120–640 mg (bid/tid)
• 2 trials have shown efficacy better than placebo but more randomized 
trials to prove its efficacy [48]
Table 7. 
Calcium channel blockers and dosage.
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41 patients who failed with treatment of valproates with 4 mg QID, 33/41 patients 
showed 50% reduction in migraine attacks, and 5 patients showed complete remis-
sion in migraine [51].
9.4 Levetiracetam (LCT)
It modifies synaptic release of glutamate/GABA by binding to specific synap-
tic protein (SV2A). Anecdotal evidence says prevention of migraine. A 10-week 
open-label study, evaluating efficacy and safety of LCT for pediatric migraine in 
a population of 30 children or adolescents aged 6–19 years, showed a reduction in 
headache frequency and severity [52].
9.5 Zonisamide
It blocks voltage-dependent sodium and T-type calcium channels and decreases 
glutamate-mediated excitatory neurotransmission. Also, it inhibits excessive NO 
production and helps in scavenging NO and hydroxyl radicals. In an open-label 
trial, 33 patients with migraine headache, refractory to other preventive therapies, 
were given a dose of 100–600 mg every third day. Results showed that 65% of 
patients had a reduction in frequency of migraine attacks [53].
9.6 Antidepressants
Possible mechanisms include reuptake inhibition of serotonin and noradrena-
line, α-adrenergic and NMDA-receptor antagonism, sodium and calcium channel 
blocking action, and potassium channel activation. Increase in GABAB receptor 
action and opioid receptor binding/opioid-mediated effect is another minor action. 
It reduces inflammation by decreasing prostaglandin (PGE2) and tumor necrosis 
factor (TNF-α). Various drugs are summarized in Table 8. Venlafaxine is used at a 
dose of 75–225 mg: a double-blind placebo controlled trial showed that the drug was 
better than placebo, starting with 37.5 mg extended release tablet/week followed by 
75 mg for another week and then 150 mg extended release in the morning [54].
9.7 Drugs acting on renin-angiotensin system
The renin-angiotensin system plays a role in neurogenic inflammation and 
causes increased susceptibility to oxidative stress. It also causes endothelial 
dysfunction and neuromodulator in nociception. Lisinopril alters sympathetic 
activity and inhibits free radical activation. It also increases prostacyclin synthe-
sis and blocks the degradation of bradykinin, substance P, and encephalin. In a 
double-blind placebo-controlled crossover study, patients aged 19–59 years with 
migraine were treated with 20 mg Lisinopril for 11 weeks—21% of patients showed 
50% reduction in migraine attacks [55]. In a comparative study of candesartan vs 
Drugs Daily doses
Amitriptyline 10–400 mg
Doxepin 10–300 mg
Nortriptyline 10–150 mg
Protriptyline 5–60 mg
Table 8. 
Antidepressant dosage.
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propranolol for migraine prophylaxis in 72 patients, 43% of patients showed greater 
than 50% reduction in migraine, and it was equally efficacious to propranolol [56].
9.8 Onabotulinum toxin
It is the FDA-approved drug for prophylaxis of chronic migraine at doses ranged 
from 155 to 195 IU, and it is injected in seven craniofacial and neck muscles, usually 
the temporalis. It inhibits neurogenic inflammation by inhibiting the release of 
nociceptive mediators like glutamate, substance P, and CGRP from the peripheral 
terminals of the efferent nerves. The analgesic action of onabotulinum toxin is 
central but yet to be proved. It will effect 3 h after injection and last for at least 7 
days. Novel delivery routes such as topical/subcutaneous applications are under 
research [57].
9.9 H3 agonists
It is used to limit the excessive inflammatory response through H3 receptor 
activation. Drugs include Nα-methylhistamine and investigational drug SCH 
50971. Phase III double-blind placebo-controlled trial for 12 weeks in 60 patients 
with a dose of 1–3 mg twice a week caused a reduction in headache frequency, 
intensity, and duration in 80% of patients. It helps in reducing the dose of 
analgesics used [58].
9.10 Tonabersat
Preclinical studies showed inhibition of cortical spreading depression by the 
drug. It inhibits neurogenic inflammation and also the gap junctional intercel-
lular communication (GJIC) between the neurons and satellite glial cells. Various 
randomized double-blind parallel group placebo-controlled multicenter studies for 
acute migraine were tried. There are conflicting reports of headache relief at 2/4 h 
and reasons are not found. In one study with 40 mg on 39 patients, it was found to 
be effective for migraine with aura when compared to that without it, reinforcing its 
inhibitory effect on CSD [59].
10. Nutraceuticals in migraine
10.1 Magnesium
Multiple studies show migraine is associated with low levels of magnesium. It 
causes an influx of calcium into the neurons, causing glutamate release into the 
neurons, which results in neuronal activation. The onset and propagation of cortical 
spreading depression is delayed and decreases. It also causes change in neurotrans-
mitter secretion and intensifies the secretion of substance P. It is used in patients with 
aura and premenstrual migraine and is used at a dose of 1, 0 g IV and 300–600 mg 
orally in chelated magnesium (taurate, glycinate, oxide) [60]. Magnesium plus 
l-carnitine is a newer preparation available.
10.2 Coenzyme Q10 (CoQ )
It promotes electron transfer from complex I and II to cytochrome C and helps 
in ATP production. It protects the mitochondria from free radical damage. A study 
of 1478 migraine patients of age range 3–22 years showed low levels of CoQ in 33% 
Migraine
10
of patients. A randomized controlled trial of 42 patients receiving 100 mg TID for 
3 months found it superior to placebo, and 48% of subjects have greater than 50% 
reduction in migraine attacks [61].
10.3 Riboflavin
It is a cofactor in the Krebs cycle. Abnormal phosphorylation of ADP to ATP is 
prevented with riboflavin. A randomized controlled trial with 400 mg riboflavin 
taken daily for 3 months was superior to placebo for reduction of migraine fre-
quency [62]. A randomized controlled trial with 400 mg of riboflavin plus feverfew 
and low-dose magnesium was comparable to a 25 mg active riboflavin. Greater than 
40% of patients showed 50% reduction in migraine attacks [63].
10.4 Vitamin B12
It helps in the conversion of homocysteine to methionine. Studies show vitamin 
B12 deficiency causes increase levels of urine methylmalonic acid levels in patients 
and worsens migraine. A possible mechanism of vitamin B12 action in migraine 
includes its excitatory role in the CNS by acting on NMDA receptors. It also plays a 
significant role in initiation, duration, and progression of migraine and activation 
of trigeminovascular system [64].
10.5 Feverfew
It is sold as capsules of dried leaves of the weed plant Tanacetum parthenium. 
Animal models show feverfew acts by inhibition of nitroglycerine-induced fos 
expression and inhibition of nuclear factor-kappa β. An open-label trial with T. 
parthenium (300 mg) plus Salix alba (white willow) for 12 weeks showed a decrease 
in pain intensity and duration of migraine. A randomized double-blind placebo-
controlled trial (riboflavin 400 mg + magnesium 300 mg + feverfew 100 mg) for 3 
months showed positive results. Recently two randomized clinical trials (RCT) of a 
purified stable extract of feverfew, MIG99, were ineffective in migraine, and clinical 
effects were very low with various complications [65].
10.6 Petasites (butterbur root)
Petasites hybridus is a potential poisonous plant but the detoxified root extract 
is safe. Mechanisms include inhibition of the synthesis of leukotrienes. It also 
decreases the intracellular concentration of calcium. It is used in the prophylaxis of 
migraine in children. A small study of 100 mg/day and a larger one of 150 mg/day 
vs placebo have shown efficacy [66].
11. Conclusion
With many newer agents now under clinical trials as well as in use, physicians 
should be aware of these drugs and their side effects, so they can use these agents 
for treating recurrent and chronic cases of migraine. Also, further well-designed 
clinical trials are needed to prove the efficacy of these agents in treatment of 
migraine. So, further research is needed to find out the safest and most effective 
treatment for chronic migraine, further designing proper animal models for study-
ing migraine, to identify newer drug targets and how to prevent the migraine at the 
patient level from acute attack going in for chronic attack.
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Abbreviations
NSAIDS nonsteroidal anti-inflammatory drugs
GJIC gap junctional intercellular communication
CGRP calcitonin gene-related peptide
NO nitric oxide
NMDA N-methyl-d-aspartate receptor
DHE dihydroergotamine
ATP adenosine triphosphate
ADP adenosine diphosphate
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Migraine
References
[1] Timothy et al. Impact of weather 
conditions on migraine in north eastern 
Nigeria. International Journal of 
Pharmacy and Pharmaceutical Sciences. 
2011;3(3):133-136
[2] Vos T, Flaxman AD, Naghavi M, 
Lozano R, Michaud C, Ezzati M. Years 
lived with disability (YLDs) for 1160 
sequelae of 289 diseases and injuries 
1990-2010: A systematic analysis for the 
Global Burden of Disease Study 2010. 
Lancet. 2012;380(9859):2163-2196
[3] Natoli JL, Manack A, Dean B, 
Butler Q , Turkel CC, Stovner L, et al. 
Global prevalence of chronic migraine: 
A systematic review. Cephalalgia. 
2009;30(5):599-609
[4] Abeer AK, Gihan SL. Flash 
dissolving sublingual almotriptan 
malate lyotabs for management of 
migraine. International Journal of 
Pharmacy and Pharmaceutical Sciences. 
2017;9(1):125-131
[5] Headache Classification Subcommittee 
of the International Headache Society. 
The International Classification of 
Headache Disorders: 2nd edition. 
Cephalalgia. 2004;24(Suppl 1):9-160
[6] Lay CL, Broner SW. Migraine in 
women. Neurologic Clinics. 2009;27(2): 
503-511
[7] Gilmore B, Michael M. Treatment 
of acute migraine headache. American 
Family Physician. 2011;83(3):271-280
[8] Simon RP, Greenberg DA, 
Aminoff MJ. Clinical Neurology. 7th ed. 
New York, NY: Lange Medical Books/
McGraw-Hill; 2009. pp. 85-88
[9] Gasparini C, Sutherland H, Griffiths L. 
Studies on the pathophysiology and 
genetic basis of migraine. Current 
Genomics. 2013;14(5):300
[10] Sarrouilhe D, Dejean C, Mesnil M. 
Involvement of gap junction channels in 
the pathophysiology of migraine with 
aura. Frontiers in Physiology. 2014;5:78
[11] Kaiser A, Russo A. CGRP and 
migraine: Could PACAP play a role too? 
Neuropeptides. 2013;47(6):451-461
[12] Kalra AA, Elliott D. Acute migraine: 
Current treatment and emerging 
therapies. Therapeutics and Clinical 
Risk Management. 2007;3(3):449
[13] Loder E. Triptan therapy in 
migraine. New England Journal of 
Medicine. 2010;363(1):63-70
[14] Lipton RB, Stewart WF, Stone AM, 
Láinez MJ, Sawyer JP. Stratified care vs 
step care strategies for migraine: The 
Disability in Strategies of Care (DISC) 
Study: A randomized trial. JAMA. 
2000;284(20):2599-2605
[15] Study Group. Stratified care vs 
step care strategies for migraine: The 
Disability in Strategies of Care (DISC) 
Study: A randomized trial. JAMA. 
2000;284(20):2599-2605
[16] Cady RK. Treating an acute attack  
of migraine. Headache. 2008;48(9): 
1415-1416
[17] Hu XH, Ng-Mak D, Cady R. Does 
early migraine treatment shorten 
time to headache peak and reduce its 
severity? Headache. 2008;48(6):914-920
[18] Foley KA, Cady R, Martin V, et al. 
Treating early versus treating mild: 
Timing of migraine prescription 
medications among patients with 
diagnosed migraine. Headache. 
2005;45(5):538-545
[19] Fox AW. Onset of effect of 
5-HT1B/1D agonists: A model with 
pharmacokinetic validation. Headache. 
2004;44(2):142-147
13
Recent Advances in Migraine Therapy
DOI: http://dx.doi.org/10.5772/intechopen.91286
[20] Ferrari MD, Goadsby PJ, Roon KI,  
Lipton RB. Triptans (serotonin, 
5-HT1B/1D agonists) in migraine: 
Detailed results and methods of a 
meta-analysis of 53 trials. Cephalalgia. 
2002;22(8):633-658
[21] Shapiro RE, Tepper SJ. The 
serotonin syndrome, triptans, and the 
potential for drug-drug interactions. 
Headache. 2007;47(2):266-269
[22] Gillman K. Serotonin toxicity. 
Headache. 2008;48(4):640-641
[23] Baron EP, Tepper SJ. Revisiting 
the role of ergots in the treatment of 
migraine and headache. Headache. 
2010;50(8):1353-1361
[24] Saper JR, Silberstein S. Pharmacology 
of dihydroergotamine and evidence 
for efficacy and safety in migraine. 
Headache. 2006;46(Suppl 4):171-181
[25] Klapper JA, Stanton J. Clinical 
experience with patient administered 
subcutaneous dihydroergotamine 
mesylate in refractory headaches. 
Headache. 1992;32(1):21-23
[26] Rabbie R, Derry S, Moore RA, 
McQuay HJ. Ibuprofen with or without 
an antiemetic for acute migraine 
headaches in adults. Cochrane 
Database of Systematic Reviews. 
2010;10:CD008039
[27] Magis D, Schoenen J. Treatment 
of migraine: Update on new therapies. 
Current Opinion in Neurology. 
2011;24(3):203-210
[28] Tfelt-Hansen P. Triptans vs other 
drugs for acute migraine. Are there 
differences in efficacy? A comment. 
Headache. 2008;48(4):601-605
[29] Lipton RB, Grosberg B, Singer RP, 
et al. Efficacy and tolerability of a new 
powdered formulation of diclofenac 
potassium for oral solution for the acute 
treatment of migraine: Results from the 
International Migraine Pain Assessment 
Clinical Trial (IMPACT). Cephalalgia. 
2010;30(11):1336-1345
[30] Jones J, Sklar D, Dougherty J, 
White W. Randomized double-blind 
trial of intravenous prochlorperazine for 
the treatment of acute headache. JAMA. 
1989;261(8):1174-1176
[31] Marmura MJ. Use of dopamine 
antagonists in treatment of migraine. 
Current Treatment Options in Neurology. 
2012;14(1):27-35
[32] Kirthi V, Derry S, Moore RA, 
McQuay HJ. Aspirin with or without an 
antiemetic for acute migraine headaches 
in adults. Cochrane Database of 
Systematic Reviews. 2010;4:CD008041
[33] Bigal ME, Bordini CA, Speciali JG. 
Intravenous chlorpromazine in the 
emergency department treatment of 
migraines: A randomized controlled 
trial. Journal of Emergency Medicine. 
2002;23(2):141-148
[34] Gallagher RM. Emergency 
treatment of intractable migraine. 
Headache. 1986;26:74-75
[35] Saper JR, Silberstein SD, 
Gordon CD, Hamel RL. Handbook of 
Headache Management. Baltimore: 
Williams & Wilkins; 1993. p. 49
[36] Krymchantowski AV, Barbosa JS. 
Dexamethasone decreases migraine 
recurrence observed after treatment 
with a triptan combined with a 
nonsteroidal anti-inflammatory 
drug. Arquivos de Neuro-psiquiatria. 
2001;59(3B):708-711
[37] Hussain A, Young WB. Steroids and 
aseptic osteonecrosis (AON) in migraine 
patients. Headache. 2007;47(4):600-604
[38] Bigal ME, Lipton RB. Excessive 
acute migraine medication use and 
migraine progression. Neurology. 
2008;71(22):1821-1828
Migraine
14
[39] Loder E. Post-marketing experience 
with an opioid nasal spray for migraine: 
Lessons for the future. Cephalalgia. 
2006;26(2):89-97
[40] Doods H, Arndt K, Rudolf K, 
Just S. CGRP antagonists: Unravelling 
the role of CGRP in migraine. 
Trends in Pharmacological Sciences. 
2007;28(11):580-587
[41] Färkkilä M, Diener HC, Géraud G, 
Láinez M, Schoenen J, Harner N, et al. 
Efficacy and tolerability of lasmiditan, 
an oral 5-HT 1F receptor agonist, for the 
acute treatment of migraine: A phase 
2 randomized, placebo-controlled, 
parallel-group, dose-ranging study. The 
Lancet Neurology. 2012;11(5):405-413
[42] Varty G, Grilli M, Forlani A, 
Fredduzzi S, Grzelak M, Guthrie D, et al. 
The antinociceptive and anxiolytic-like 
effects of the metabotropic glutamate 
receptor 5 (mgluR5) antagonists, 
MPEP and MTEP, and the mgluR1 
antagonist, LY456236, in rodents: 
A comparison of efficacy and side-
effect profiles. Psychopharmacology. 
2005;179(1):207-217
[43] Silberstein SD. Practice parameter: 
Evidence-based guidelines for migraine 
headache (an evidence-based review): 
Report of the Quality Standards 
Subcommittee of the American 
Academy of Neurology. Neurology. 
2000;55(6):754-762
[44] Buchanan TM, Ramadan NM. 
Prophylactic pharmacotherapy for 
migraine headaches. Seminars in 
Neurology. 2006;26(2):188-198
[45] Bigal ME, Krymchantowski AV, 
Rapoport AM. Prophylactic migraine 
therapy: Emerging treatment options. 
Current Pain and Headache Reports. 
2004;8:178-184
[46] Kaniecki RG. Migraine prevention 
with Carvedilol: A prospective, open-
label trial. Headache. 2003;43:589
[47] Pietrobon D. Calcium channels and 
channelopathies of the central nervous 
system. Molecular Neurobiology. 
2002;25:31-50
[48] Solomon GD. Verapamil in migraine 
prophylaxis-a five-year review. 
Headache: The Journal of Head and Face 
Pain. 1989;29(7):425-427
[49] Freitag FG, Collins SD, Carlson HA, 
et al. A randomized trial of divalproex 
sodium extended-release tablets in 
migraine prophylaxis. Neurology. 
2002;58:1652-1659
[50] Shank RP, Gardocki JF, Streeter AJ, 
Maryanoff BE. An overview of the 
preclinical aspects of topiramate: 
Pharmacology, pharmacokinetics, 
and mechanism of action. Epilepsia. 
2000;41(Suppl 1):S3-S9
[51] Freitag FG, Diamond S, 
Diamond ML, et al. The prophylaxis 
of migraine with the GABA-agonist, 
tiagabine: A clinical report. Headache. 
1999;39:354
[52] Vaisleb I, Neft R, Schor N. Role 
of Levetiracetam in prophylaxis of 
migraine headaches in childhood. 
Neurology. 2005;64:A343
[53] Krusz JC. Zonisamide in the 
treatment of headache disorders. 
Cephalalgia. 2001;21:374-375
[54] Ozyalcin SN, Talu GK, Kiziltan E, 
Yucel B, Ertas M, Disci R. The efficacy 
and safety of venlafaxine in the 
prophylaxis of migraine. Headache. 
2005;45:144-152
[55] Schrader H, Stovner LJ, Helde G,  
Sand T, Bovim G. Prophylactic 
treatment of migraine with angiotensin 
converting enzyme inhibitor 
(lisinopril): Randomized, placebo 
controlled, crossover study. BMJ. 
2001;322:19-22
[56] Tronvik E, Stovner LJ, Helde G,  
Sand T, Bovim G. Prophylactic 
15
Recent Advances in Migraine Therapy
DOI: http://dx.doi.org/10.5772/intechopen.91286
treatment of migraine with an 
angiotensin II receptor blocker: A 
randomized controlled trial. JAMA. 
2003;289:65-69
[57] Ashkenazi A, Silberstein AD.  
Botulinum toxin and other new 
approaches to migraine therapy. 
Annual Review of Medicine. 2004;55: 
505-518
[58] Millán-Guerrero RO, Pineda-Lucatero AG, 
Hernández-Benjamín T, Tene CE, 
Pacheco MF. Nα-methylhistamine safety 
and efficacy in migraine prophylaxis: 
Phase I and phase II studies. Headache: 
The Journal of Head and Face Pain. 
2003;43(4):389-394
[59] Hauge AW, Asghar MS,  
Schytz HW, Christensen K, Olesen J. 
Effects of tonabersat on migraine with 
aura: A randomized, double-blind, 
placebo-controlled crossover study. The 
Lancet Neurology. 2009;8(8):718-723
[60] Peikert A, Wilimzig C, 
Kohne-Volland R. Prophylaxis of 
migraine with oral magnesium: Results 
from a prospective, multi-center, 
placebo-controlled and double-blind 
randomized study. Cephalalgia. 
1996;16:257-263
[61] Sandor PS, Di Clemente L, 
Coppola G, et al. Efficacy of coenzyme 
Q10 in migraine prophylaxis: A 
randomized controlled trial. Neurology. 
2005;64:713-715
[62] Schoenen J, Jacquy J, Lenaerts M. 
Effectiveness of high-dose riboflavin in 
migraine prophylaxis: A randomized 
controlled trial. Neurology. 1998;50: 
466-470
[63] Maizels M, Blumenfeld A, 
Burchette R. A combination of riboflavin, 
magnesium, and feverfew for migraine 
prophylaxis: A randomized trial. 
Headache. 2004;44:885-890
[64] Bianchi A, Salomone S, Caraci F, 
Pizza V, Bernardini R, D’Amato CC. 
Role of magnesium, coenzyme Q 10, 
riboflavin, and vitamin B 12 in migraine 
prophylaxis. Vitamins & Hormones. 
2004;69:297-312
[65] Pittler MH, Ernst E. Feverfew 
for preventing migraine. Cochrane 
Database of Systematic Reviews. 2004;1: 
CD002286
[66] Lipton RB, Gobel H, Einhaupl KM, 
Wilks K, Mauskop A. Petasites hybridus 
root (butterbur) is an effective 
preventive treatment for migraine. 
Neurology. 2004;63:2240-2244
[67] Giffin NJ, Kowacs F, Libri V, 
Williams P, Goadsby PJ, Kaube H. Effect 
of the adenosine A1 receptor agonist 
GR79236 on trigeminal nociception with 
blink reflex recordings in healthy human 
subjects. Cephalalgia. 2003;23(4):287-292
[68] Lassen LH, Ashina M, 
Christiansen I, Ulrich V, Grover R, 
Donaldson J, et al. Nitric oxide synthase 
inhibition: A new principle in the 
treatment of migraine attacks. 
Cephalalgia. 1998;18(1):27-32
[69] Tfelt H. Site of effect of LY2951742 
for migraine prophylaxis. The Lancet 
Neurology. 2015;14(1):31-32
[70] Chabi A, Zhang Y, Jackson S, 
Cady R, Lines C, Herring WJ, et al. 
Randomized controlled trial of the 
orexin receptor antagonist Filorexant 
for migraine prophylaxis. Cephalalgia. 
2015;35(5):379-388
[71] Meents J, Neeb RU. TRPV1 in 
migraine pathophysiology. Trends in 
Molecular Medicine. 2010;16(4):153-159
[72] Vogler B, Rapoport A, Tepper S, 
Sheftell F, Bigal M. Role of melatonin in 
the pathophysiology of migraine. CNS 
Drugs. 2006;20(5):343-350
[73] Magni G, Ceruti S. P2Y purinergic 
receptors: New targets for analgesic 
and antimigraine drugs. Biochemical 
Pharmacology. 2013;85(4):466-477
